Committee on Addiction Psychiatry
Chair, Jeremy Kidd, M.D., M.P.H.

Committee Charge

1. To encourage participation of NYCPS psychiatrists interested in the treatment of substance use disorders (SUDs).
2. To be available to the Officers, Executive Council, and other Committees and Task Forces of NYCPS for consultation when matters concerning SUDs in arise, including policy and legislative matters.
3. To encourage ongoing education within NYCPS on topics related to addiction psychiatry, including the evaluation, diagnosis, and evidence-based treatment for SUDs.
4. To advocate for policies and programs that expand the availability of evidence-based SUD treatments and that reduce stigma faced by people with SUDs.
5. To serve a liaison function between NYCPS and other addiction-focused organizations in New York City (e.g. Area 2 of the American Academy of Addiction Psychiatry).

*If you would like more information about this committee, please contact us at [email protected]


Upcoming Events

Check back soon for this Committee's upcoming events in the fall!


Previous Events

Medical Marijuana: Evidence base and the promises of Cannabidiol (CBD)
March 26, 2019

This seminar, held at Lenox Hill Hospital, addressed evidence for and against medical marijuana, including the question of cannabidiol (CBD). The regulations and logistics governing prescription of medical marijuana in New York State were reviewed. Speaker, Diana Martinez, M.D., Professor of Psychiatry at the Columbia University Irving Medical Center presented. Her research career has focused on the neurochemistry of addiction and the pharmacology substances of abuse. Recent work has included the cannabinoid system, including its potential for therapeutic use. 

Fentanyl - A New Chapter in the Opioid Epidemic
September 25, 2018

Fentanyl, an opioid 50 times more potent than heroin, is increasingly implicated in opioid overdose deaths. More often than ever before, fentanyl is being added to heroin and other drugs such as cocaine. This represents a new chapter in the opioid epidemic. In this presentation, Sandra Comer, PhD reviewed the neurobiology of fentanyl and described the clinical and policy implications of fentanyl's increasing presence in the drug supply.